Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene is one step closer to China OK for PD-1
China is reportedly approving its 6th PD-1(L)1 drug in just over a year — and Amgen will be pleased with this one.
The OK for tislelizumab would be the first marketed product to be developed by BeiGene, the eminent Beijing-based biotech that Amgen recently took a $2.7 billion stake in. China’s Center for Drug Evaluation has completed technical review and sent the NDA to the National Medical Products Administration with a recommendation to approve, Chinese media outlet Jiemian reported.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.